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Effect of proteinuria reduction on prevention of focal glomeru- leakage and the nephrotoxic effects of the systemic state
losclerosis by ACE inhibition is modifiable. of nephrosis are assumed to be involved in proteinuria-
Background. Proteinuria is associated with a progressive induced renal damage [2–10]. By comparing renal dam-loss of renal function; we recently found that both intrarenal
age in nephrosis induced by unilateral and bilateral pro-effects of proteinuria and the state of systemic nephrosis play
teinuria (that is, adriamycin nephrosis induced by ex-an independent role in proteinuria-induced renal damage. Re-
duction of proteinuria is an important mechanism underlying posing only one vs. both kidneys to adriamycin), we
the renoprotective effect of angiotensin-converting enzyme in- recently demonstrated an independent role for the intra-
hibition (ACEi). Both the reduction of proteinuria and the renal effects of protein leakage and the effects of the
attenuation of the systemic state of nephrosis may be involved
systemic sequelae of nephrosis, such as hyperlipidemiain the renoprotection by ACEi.
[11]. In this study, for a given proteinuria per kidney,Methods. This article entails a post hoc analysis of a previous
study on the renoprotective effect of ACEi lisinopril in adria- glomerulosclerosis was twice as severe in the animals
mycin nephrosis. It was attempted to modify therapeutic effi- with bilateral proteinuria, that is, the animals with more
cacy of ACEi by increasing lisinopril dose and by dietary so- severe systemic nephrosis. This demonstrates that the
dium restriction, respectively. In this analysis, we aimed to severity of renal damage induced by a certain glomerulardelineate the contribution of proteinuria reduction and the
protein leakage is, to a large extent, modified by thereduction of other intermediate parameters such as hyperlipid-
simultaneous presence of other factors, which could, foremia and blood pressure on the protection against focal glomer-
ulosclerosis (FGS). instance, be the nephrosis-induced hyperlipidemia.
Results. We found that in adriamycin nephrosis, ACEi sig- The reduction of proteinuria is assumed to be an im-
nificantly reduced proteinuria, lipids, and blood pressure and portant mechanism underlying the renoprotective effectprovided protection against FGS. Treatment modification by
of angiotensin-converting enzyme inhibition (ACEi)increasing the lisinopril dose resulted in a further reduction of
[12]. Therapeutic measures aimed at the enhancementFGS without significant effects on intermediate parameters
(proteinuria, hyperlipidemia, and blood pressure), whereas sur- of antiproteinuric efficacy may therefore improve reno-
prisingly, treatment modification by sodium restriction resulted protection. Both attenuation of intrarenal effects of pro-
in a further attenuation of intermediate parameters, without tein leakage and amelioration of systemic nephrosis (for
additional protection against FGS.
example, hyperlipidemia) could be expected to contrib-Conclusions. The renoprotective benefit of an obtained at-
ute to improved protection against focal glomeruloscle-tenuation of intermediate parameters is modified by other fac-
tors. Further optimization of renoprotective therapy requires rosis (FGS) [13–19]. The relative contribution of these
identification of such factors and explicit consideration of ther- factors in the protection against FGS, however, is un-
apeutic efficacy on intermediate parameters as well as hard known.
end points. This article entails a post hoc analysis of a previous
study in which the renoprotective effect of ACEi lisino-
pril was studied in adriamycin nephrosis [20]. In the
Proteinuria is associated with a progressive loss of original study, it was attempted to enhance the therapeu-
renal function in humans as well in experimental renal tic efficacy of ACEi by increasing lisinopril dose and by
disease [1]. Both intrarenal effects of glomerular protein dietary sodium restriction, respectively. In the current
analysis, we aimed to delineate the contribution of pro-
teinuria reduction and the reduction of other intermedi-Key words: glomerulosclerosis, cholesterol, adriamycin nephrosis,
sodium restriction, lisinopril. ate parameters, such as hyperlipidemia and blood pres-
sure, on the protection against FGS. 1999 by the International Society of Nephrology
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METHODS tween groups were performed using Student’s t-test. Sta-
tistical significance was assumed at the 5% level.Adult male Wistar rats were studied (Harlan, Zeist,
The Netherlands). Throughout the experiment, the ani-
mals were housed in a temperature-controlled room with RESULTS
a 12-hour light-dark cycle. Throughout the first five
During the course of the experiment, five rats diedweeks, all animals received a low-sodium diet (LS; 0.05%
in the NS diet groups and five in the LS diet groups.NaCl, 20% protein). After stabilization of proteinuria
Adriamycin induced a marked and relatively stable pro-(5 weeks), the animals were matched for proteinuria,
teinuria five to six weeks after induction (593 6 31 mg/
blood pressure, and body weight. Thirty-six animals were
24 hr). After an initiation of treatment proteinuria re-
then switched to a normal-sodium diet (NS; 0.3% NaCl,
mained unaltered in both vehicle-treated groups, no dif-
20% protein), whereas the other 48 animals continued
ference in proteinuria, lipids, blood pressure, or FGS
on a LS diet for the remainder of the study. After a
was present between the LS and NS groups.
week of stabilization on these diets, the rats received
Lisinopril resulted in a significant reduction of blood
different doses of lisinopril in their drinking water: 0, 2,
pressure, proteinuria, lipids, and FGS for all groups
and 5 mg/kg/24 hr (each N 5 12) until the end of the
taken together, as compared with vehicle. The initial
study (week 12). To provide a larger dose range on
reduction in proteinuria in the treated animals (r 5 0.59,
LS, 12 additional LS animals received 10 mg/kg/24 hr
P , 0.01), as well as residual proteinuria at week 12 (r 5
lisinopril.
0.71, P , 0.01), correlated with the outcome as to FGS.
Once a week during the entire protocol of 12 weeks,
In addition, cholesterol at week 12 (r 5 0.54, P , 0.01)
all rats were weighed. Twenty-four hour urine was col-
correlated with FGS as well. There was no correlation
lected in metabolic cages with free access to food and between the initial blood pressure-lowering effect and
water, and blood pressure was measured by the tail-cuff the final FGS score.
method. Body weight, food intake, and water intake The effects of different doses of lisinopril in the LS
were measured weekly. These parameters were not dif- groups are shown in Figure 1A. Lisinopril significantly
ferent for the studied groups throughout the experiment. reduced proteinuria, cholesterol, triglycerides, and blood
At the end of the study, blood was collected. Kidneys pressure. The effect on proteinuria and lipids was already
were perfused with saline. The animals were sacrificed, maximal at the 2 mg/kg dose. Blood pressure reduction
and the kidneys were harvested for histological examina- tended to be more effective at higher doses, but the
tion. difference between the dose groups did not reach statisti-
The urinary protein concentration was determined by cal significance. FGS was attenuated in all lisinopril
a biuret method (Bioquantt; Merck, Darmstadt, Ger- groups as compared with vehicle; the reduction reached
many). Serum cholesterol and triacylglycerols were mea- a statistical difference for the 5 and 10 mg/kg dose.
sured by a standard autoanalyzer technique (SMA-C; The effects of sodium intake during lisinopril treat-
Technicon, Tarrytown, NY, USA). Tissue processing ment are shown in Figure 1B. In the LS animals, protein-
was performed as described earlier [21]. Focal segmental uria, cholesterol, triglycerides, and blood pressure were
glomerulosclerosis was scored semiquantitatively on a considerably and significantly lower during lisinopril
scale of 1 to 4. Focal segmental glomerulosclerosis was than in NS animals. However, in spite of these differ-
scored positive when mesangial expansion, mesangial ences in intermediate parameters, no differences were
cellularity, adhesion formation, and capillary oblitera- found in FGS.
tion were present in one segment. If 25% of the glomeru-
lus was affected, a score of 1 was given. Fifty percent
CONCLUSIONSwas scored as 2. Seventy-five percent as 3, and 100% as
4. The ultimate score was then obtained by multiplying In this model of proteinuria-induced renal damage,
the degree of change by the percentage of glomeruli with ACEi reduced proteinuria, lipids, and blood pressure
the same degree of injury and adding these scores. A and provided protection against FGS. The protection
total number of 50 glomeruli per kidney were scored, against FGS was predicted by the efficacy of proteinuria
moving from cortex to medulla. reduction and also by the attenuation of the systemic
manifestations of nephrosis, as indicated by the choles-
Data analysis terol level during treatment. These findings confirm the
Data are expressed as mean 6 sem. To compare the role of proteinuria and hyperlipidemia as surrogate or
effects of lisinopril during LS versus NS, pooled data for intermediate parameters for protection against renal
the 2 and 5 mg/kg dose were analyzed. Tukey’s method damage. Two possible strategies to improve antiprotein-
was used for comparison of groups receiving different uric, and thus renoprotective efficacy, were evaluated,
that is, the use of increasing doses of ACEi, and concomi-doses of lisinopril. The other statistical comparisons be-
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Fig. 1. (A) The effects of lisinopril treatment
in different doses (0, 2, 5, and 10 mg/kg) in
low-sodium rats after six weeks of treatment.
Abbreviations and symbols are: PROT ( ),
urinary protein (mg/24 hr); CHOL ( ),
plasma cholesterol (mmol/liter); TG ( ),
plasma triglycerides (mmol/liter); SBP, sys-
tolic blood pressure (mm Hg); FGS, sclerosis
index (%). Data are expressed as mean 6 sem.
*P , 0.01 vs. no lisinopril treatment (0 mg/
kg). (B) The effects of dietary sodium intake
during lisinopril treatment (LS, 2 and 5 mg/
kg vs. NS, 2 and 5 mg/kg) after six weeks of
treatment. Data are expressed as mean 6 sem.
*P , 0.01 vs. normal-sodium diet.
tant sodium restriction. Increasing the dose of lisinopril dose than optimal blood pressure reduction, but no data
on dose dependency of long-term renal outcome areresulted in a further reduction of FGS without significant
effects on intermediate parameters, whereas treatment available. In accord with our findings, Ikoma et al found
that a higher dose of ACEi resulted in additional protec-modification by sodium restriction did not result in addi-
tional protection against FGS, despite significant further tion against FGS in the remnant kidney model without
further effect on intermediate parameters blood pressureattenuation of intermediate parameters.
The dose response for renoprotection by ACEi has and glomerular hemodynamics [24]. Considering the evi-
dence for a role of angiotensin II as a modulator ofnot been well established. In particular, it is unknown
whether the dose response for the eventual protection processes of growth and matrix production [25], it was
postulated that higher doses of ACEi provide additionalagainst progressive renal damage equals the dose re-
sponse for intermediate parameters such as lipids, blood renoprotection by nonhemodynamic actions such as
modulation of the effect of angiotensin II on the dynamicpressure, and proteinuria. Studies in humans suggest dif-
ferences between the ACEi dose-response for different balance between production and degration of mesangial
matrix. Preliminary data on reduction of renal trans-intermediate parameters [22, 23], as the optimal reduc-
tion of proteinuria appears to require a higher ACEi forming growth factor-b by high-dose ACEi seem to
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support this assumption (abstract; Peters et al, J Am Soc by demonstrating that a renoprotective benefit of an
obtained attenuation of intermediate parameters suchNephrol 8:A2438, 1997). As for our study, blood pressure
tended to be somewhat lower at high dose ACEi, albeit as proteinuria, lipids, and blood pressure is presumably
modified by other factors. The nature of these factorsnot significantly so. Therefore, we cannot reliably ex-
clude that a lower blood pressure contributed to the remains to be elucidated. These data during intervention
are in line with our previous finding that the damagingadditional renoprotection at a high dose of ACEi.
During sodium restriction, the effects of ACEi on all effect of a given proteinuria is modified by other factors
[11]. Unfortunately, in this study, we were not able tointermediate parameters were enhanced to a consider-
able extent, which is in accord with previous findings in delineate the separate roles of the different intermediate
parameters in renoprotection, as treatment modificationhumans [10, 26, 27]. Unexpectedly, however, this did not
result in a corresponding reduction in FGS. Our data resulted in parallel changes in proteinuria and hyperlip-
idemia and a more or less parallel change in blood pres-provide no readily available explanation for this finding.
It could be argued that the level of FGS in NS rats sure.
Elucidation of the intrarenal mechanisms of reno-approximates the amount of FGS normally found in this
rat strain, thus precluding further improvement. This protection by intervention in specific risk factors, and
identification of modifying factors, may help to improvestudy did not include healthy controls to substantiate
this assumption. In another study, we found an FGS renoprotective efficacy further. Whereas monitoring of
intermediate end points, such as proteinuria, hyperlipid-score of 3 6 1 in healthy Wistar rats [11], and moreover,
in this study, the 10 mg dose of ACEi reduced FGS to emia, and blood pressure, is highly important especially
in clinical studies, our data show that assessment of their9 6 3, suggesting that a lack of further improvement by
LS is not explained by already having obtained the lowest relationships to hard end points is indispensable for the
improvement of renoprotective therapy.possible FGS score on NS.
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